Roche (ROG: SIX) has been granted US approval for Phesgo (pertuzumab/trastuzumab/hyaluronidase) plus chemo, for the treatment of early and metastatic HER2-positive breast cancer.
Administered by subcutaneous injection, Phesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, in combination with intravenous chemotherapy.
It is the first time the Swiss cancer giant has combined two monoclonal antibodies that can be administered by a single subcutaneous injection, providing a convenient and patient-friendly mode of administration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze